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Personalized prediction of EGFR
mutation-induced drug resistance in lung
cancer
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1Department of Electronic Engineering, City University of Hong Kong, Kowloon, Hong Kong, 2Li Ka Shing Faculty of Medicine, The
University of Hong Kong, Pokfulam, Hong Kong.
EGFR mutation-induced drug resistance has significantly impaired the potency of small molecule tyrosine
kinase inhibitors in lung cancer treatment. Computational approaches can provide powerful and efficient
techniques in the investigation of drug resistance. In our work, the EGFR mutation feature is characterized
by the energy components of binding free energy (concerning the mutant-inhibitor complex), and we
combine it with specific personal features for 168 clinical subjects to construct a personalized drug resistance
prediction model. The 3D structure of an EGFR mutant is computationally predicted from its protein
sequence, after which the dynamics of the bound mutant-inhibitor complex is simulated via AMBER and
the binding free energy of the complex is calculated based on the dynamics. The utilization of extreme
learning machines and leave-one-out cross-validation promises a successful identification of resistant
subjects with high accuracy. Overall, our study demonstrates advantages in the development of personalized
medicine/therapy design and innovative drug discovery.
N
on-small-cell lung cancer (NSCLC) has become a major threat to human health1. Mutations, such as in-
frame deletions or amino acid substitutions, clustered around the ATP-binding pockets of the tyrosine
kinase domain of the epidermal growth factor receptor (EGFR) are the primary cause of NSCLC1–3. In
clinical treatment of NSCLC, tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are widely used3,4.
These two reversible inhibitors show stronger binding affinity with mutant kinases than the wild-type (WT)
EGFR, and they indeed produce good results for many patients for a period of time2.
However, the effectiveness of these inhibitors is limited by the emergence of drug resistance, sometimes due to a
second mutation, such as the substitution of threonine with methionine at residue site 7902,3. The cause of drug
resistance is thought to be steric interference with the binding of inhibitors caused by the mutations5–7.
Irreversible inhibitors including CL387/785, EKB-569, and HKI-272 are proposed to tackle the problem5,6,8–10.
However, the EGFR structure will be chemically modified via a covalent bond2, which is not encouraged in
practical therapy. Therefore, the EGFR mutation-induced drug resistance leads to an urgent demand to develop
new treatment strategies11,12.
With the rapid development of bioinformatics, computational methods13,14 have become more efficient and
popular for studying the molecular mechanism ofmutation-induced drug resistance, developing predictive tools,
and designing resistance-evading drugs4,11,12,15. These computational approaches are investigated based on the
genotypic data, which fall into two categories: sequence-based and structure-based approaches. With the util-
ization of three-dimensional (3D) structural information16, machine learning and pattern classification methods
such as neural networks17–19, support vector machines (SVM)20 and decision trees21 have shown high potential in
the prediction of drug resistance and innovative drug design11.
In this paper, we present a method that combines the EGFR-inhibitor interaction pattern and the specific
personal features for each of our 168 clinical subjects to construct a personalized drug resistance prediction
model. Our method can have useful applications to the development of personalized medicine/therapy. In this
method, mutations in protein sequences of the EGFR kinase domain are initially translated into the 3D structures
based on a template structure, using protein structure prediction tools scap22 and loopy23. AMBER24 is employed to
simulate the dynamics of the kinase mutant-inhibitor systems and evaluate the binding free energies of the
mutants and inhibitors. We then characterize the EGFR-inhibitor interaction by the energy components of
the binding free energy extracted via MM/PBSA in AMBER24. These interaction patterns coupled with specific
personal features of our subjects are regarded as main characteristics for further classification. Extreme learning
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machines (ELMs)25,26 are adopted here together with leave-one-out
cross-validation. These structural analyses provide us with insights
into the mechanism of mutation-induced drug resistance at the
molecular level, which play an important role in personalized ther-
apy design and innovative drug discovery.
Results
Inhibitors. Gefitinib (IRESSATM) and erlotinib (TARCEVAH) are
the main inhibitors used in EGFR-targeted therapy. We isolate
them from their bound complexes 2ITY and 1M17 downloaded
from the Protein Data Bank (PDB)16. Their 3D structures can be
viewed in Figure 1 (parts a and b). The General AMBER Force
Field (GAFF), which covers most of the organic chemical space, is
implemented to generate the topology and coordinate files of the
inhibitors. Based on GAFF, the antechamber program in AMBER24
assigns atomic charges and atom/bond types for the inhibitors, and
further constructs their topology files. The AM1-BCC charge
method27, which efficiently reproduces the HF/6-31G* RESP
charge, is employed when adding atomic charges.
Results for the modeling of mutant-inhibitor complexes. In our
study, we focus on the mutations on exons 18 , 21 of the EGFR
tyrosine kinase domain. Specifically, we carried out clinical
observations on 168 lung-cancer patients from the Queen Mary
Hospital in Hong Kong. These patients are then mapped from
their genotypes into a total of 37 mutation types of the WT EGFR
kinase protein. We notate these mutation types by their cor-
responding changes in protein sequences relative to the WT
sequence, as the following principles (refer to Supplementary Table
1 for an overall list).
. Residue substitution of X with Y at residue site I is denoted by
XIY, such as L858R.
. Deletion of residues at sites I (residue X) to II (residue Y) is
denoted by delXI_YII, such as delE746_A750.
. Duplication of residues at sites I (residue X) to II (residue Y) is
represented as dulXI_YII, such as dulS768_D770.
. Modification of residues at sites I (residue X) to II (residue Y) is
denoted by a combination of deletion and insertion (delXI_
YIIinsk, k is a residue list), such as delL747_A755insSKG.
. Adouble-pointmutation ofXwithY at residue site I andAwithB
at residue site II is named by two single-point mutations con-
nected by an underscore, such as T854A_L858R.
Further, we carry out statistics for these mutation types on our
patients and derive that mutation types L858R (80 cases),
delE746_A750 (38 cases) and delL747_P753insS (10 case) occupy
the majority of the patients, while the others are considered as rare
mutations. For simplicity in our later interpretation, we name the
mutants the same as their corresponding mutation types, such as
mutant L858R and mutation type L858R.
Subsequently, we translate these mutations from protein se-
quences into their 3D structures. A mutated protein structure is
determined based on homology modeling. Different types of muta-
tions are then obtained using two programs, scap22 and loopy23. First,
the template protein structures extracted from complex 2ITZ and
2ITY are prepared. Scap deals with side chain substitutions. It packs
side chains that are selected from a previously constructed rotamer
library28, according to the energy preferences coupled with steric
feasibility29. Meanwhile, loopy handles both residue deletion and
insertion. The core of loopy is the solution of a mini protein folding
problem. Accordingly, it samples the conformation space with con-
Figure 1 | 3D structures of inhibitors, computationally predicted mutants and complexes. Parts (a) and (b) show the 3D structures of inhibitors
gefitinib (IRESSATM) and erlotinib (TARCEVAH) respectively. In parts (c) to (g), we present a comparison between the mutation neighborhood of our
computationally predictedmutant and the corresponding site of theWTEGFR kinase protein, for a specificmutation type. Eachwhite chain corresponds
to theWT structure, and each blue one is ourmodeling result. Accordingly, parts (c) to (g) show themutation types L858R, delL747_P753insS, dulH773,
delE746_A750, and T854A_L858R respectively. Parts (h) and (i) display the inhibitor-binding pocket of mutant delE746_A750 with inhibitors gefitinib
and erlotinib respectively.
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straints of closure30 and steric feasibility29, and scores the candidates
based on the colony energy23. Some examples of the modeling results
are displayed in Figure 1 (parts c to g). The 3D structures are dis-
played using UCSF Chimera31. For each sampled structure we carry
out a rough minimization32, where the maximum number of min-
imization steps is set as 5000 with the first 2500 steps performed
using the steepest descent algorithm. Inhibitors (gefitinib and erlo-
tinib) are separately aligned to the binding pocket of each mutant
structure, to construct their bound complexes. As an example, the
binding pocket of mutant delE746_A750 for gefitinib and erlotinib is
exhibited in Figure 1 (parts h and i).
Furthermore, for the three dominant mutation types from our
observed patients, namely L858R, delE746_A750 and delL747_
P753insS, we carry out a brief exploration in Figure 2 on themodeled
mutant-inhibitor complex structures, with the WT-inhibitor system
used for a comparison. In this figure, we comparably display the
inhibitor-binding pocket andmutation site of eachmutant and those
sites of theWT protein. We can see that, the frequently mutated sites
are located in the loops at the margin or neighborhood of the inhib-
itor-binding pocket. It is well acknowledged that, loops23,29 are more
flexible than other protein secondary structures, such as a–helixes
and b-sheets33, which to some extent explains why these mutations
occur easily and frequently in the WT structure. A comprehensive
survey in the future will provide deeper insights into these structures.
Molecular dynamics (MD) simulations. Each acquired mutant-
inhibitor complex is then computationally solvated into a water
box. The dynamics of the complex is simulated in this solvent
environment. Prior to the crucial MD simulation, the entire system
should be equilibrated to a stable state.We employ sander in AMBER
for a series of equilibrating operations, which incorporates a short
1000-stepminimization (the first half with the steepest descent steps)
to remove bad contacts, a 50-picosecond (ps) heating (0 , 300 K)
and a 50 ps density equilibration with weak restraints (weight of 2.0)
from a harmonic potential on the mutant-inhibitor complex, and a
500 ps constant pressure equilibration at 300 K. All simulations are
performed with SHAKE constraints on hydrogen atoms to remove
their bond stretching freedom, and the Langevin dynamics is
adopted for an efficient temperature control. The equilibration of
each system is verified through observing the temperature, density,
energy and backbone root-mean-square deviation (RMSD) of each
system.
Once each system equilibration is achieved, we generate the
production MD simulation for 2 nanoseconds (ns), where we
collect trajectory frames at a step of 10 ps and 200 frames in each
trajectory. A stable backbone RMSD in each system is an apparent
indicator of the stabilization of the production MD simulation,
which guarantees a posterior reliable calculation of the binding
free energy. For each system, the backbone RMSD distribution
over the simulation period (2 ns) is investigated. As an example,
the plots for trajectory vs. backbone RMSD in this period, with
regard to several major systems, are shown in Figure 3. These
systems each incorporate an EGFR kinase protein (WT, L858R,
delE746_A750 or delL747_P753insS) and an inhibitor (gefitinib or
erlotinib). In this figure, the backbone RMSD values show an
acceptable level of stabilization for each system.
Binding free energy. The production MD simulations produce the
motion trajectories of the solvated mutant-inhibitor systems, and the
binding free energies are calculated based on these trajectories. Binding
free energy is a quantitative estimate of the binding affinity of a solvated
receptor-ligand system. Based on the computations of different types of
free energy differences, MMPBSA in AMBER derives the binding free
energies, which encompass energy components of Van der Waals
forces (VDW), electrostatic interactions (EEL), and the polar (EPB)
and non-polar (ENPOLAR) terms of the solvation free energies. For
the WT protein and observed mutants, we calculate their binding free
energies with the two inhibitors gefitinib and erlotinib respectively. The
detailed information of these energies and their components can be
referred to in Supplementary Table 1.
We further examine the distributions of these obtained binding
free energies and their components (VDW, EEL, EPB and
ENPOLAR) in Figure 4 (parts b to e). The distribution of the binding
free energy of these mutants (with WT protein included) with gefi-
nitinib is displayed in part b of Figure 4, and that with erlotinib
involved is shown in part d. For both inhibitors gefitinib and erloti-
nib, the binding free energies with these mutants scatter around that
with the WT protein (denoted by red lines). Especially, for mutation
L858R that is a common cause of lung cancer, the binding free energy
of the mutant with an inhibitor (marked with solid blue circles) is
lower than that of theWTprotein. In parts c and e of Figure 4, we give
the distributions of the binding free energy components coupledwith
that of the total energy, separately concerning the two inhibitors. The
extracted energy components VDW, EEL, EPB and ENPOLAR pos-
sess different distributions to the total energy, which may reveal
potential significant features for these mutation types. On the other
hand, we display the statistics for the mutation types on our 168
patients in part a of Figure 4, where the three peaks are L858R,
delE746_A750 and delL747_P753insS respectively, as aforemen-
tioned.
Computational prediction of drug resistance. The potency of an
inhibitor in the treatment of a specific patient can be measured by its
survival time or response level. In clinical observations, survival time
Figure 2 | A comparison between the mutant-inhibitor complex and the
WT-inhibitor complex structures for several major mutation types. In
each diagram, a portion of a WT/mutant-inhibitor complex is presented,
with the inhibitor (gefitinib) colored pink and the original/mutation site
colored blue. Diagrams (a) and (b) show a comparison between the WT-
gefitinib system and the L858R-gefitinib system. Similarly, diagrams (c),
(d) and (e) , (f) show mutations delL747_P753insS and delE746_A750
respectively.
www.nature.com/scientificreports
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is generally recorded in unit of months or days, corresponding to a
continuous variable in computation. Response level can be divided
into four categories and thus mapped into a discrete variable ranging
in [1, 4]. Each of our 168 patients has been clinically observed and
recorded by RECIST in his treatment involving a specific inhibitor
(gefinitib or erlotinib).
Firstly, we simply examine how the computed binding free energy
(total energy) relates to the survival time or response level. For a
specific patient, the feature of binding free energy (and energy com-
ponents) can be derived from his/her EGFRmutation type combined
with the inhibitor used in his/her treatment (checked in
Supplementary Table 1). Gefitinib is applied in majority of the treat-
ments for the 168 patients (137 cases of gefitinib, 31 cases of erloti-
nib). To normalize the potency of the two inhibitors (gefinitib and
erlotinib), we set the binding free energies of theWT protein with the
two inhibitors as baselines, which implies that for each case concern-
ing a mutation type and an inhibitor we subtract the baseline value
from its binding free energy (same for the components) to obtain the
final energy-related feature. We call the energy-related feature
‘‘mutation feature’’ for short in the following interpretation. In part
a of Figure 5, we plot the distribution of mutation feature (which
represents the total binding free energy) vs. survival time, and that of
mutation feature vs. response level is displayed in part b. Fromparts a
and b of Figure 5, we find that the mutation feature is not one-to-one
related or linearly related to the survival time or response level, which
demonstrates the influence of individual difference on the potency of
an inhibitor.
Personal information of each patient is recorded as well. The
personal information, which is referred to as ‘‘personal features’’ in
later interpretation, incorporates basic descriptive features and
symptoms. Detailed items include age, gender, smoking history, per-
formance status, subtypes of the NSCLC, stages describing the
development of the NSCLC, brain metastasis and suspension of
TKIs. For simplicity, we further discretize the original age values into
ranges (0, 50), [50, 60), [60, 70), [70, 80), [80, 200), which is finally
mapped into a discrete range of [0, 4]. Detailed information for all
these personal features is provided in Table 1.
We next combine the personal features with the mutation feature
for each patient, leading to a total of 168 subjects, to develop a drug
resistance prediction model (to predict response level). Before build-
ing the model, we normalize each feature of the whole feature set (15
features) into a range of [21, 1] to compensate the differences. The
distributions of values of these features (personal1mutation) for the
168 subjects are shown in parts c and d of Figure 5. Part c gives the
original distribution while part d exhibits the normalized values.
Extreme learning machines (ELMs) are used for building a clas-
sification model, in which an optimal set of weights and biases are
determined by finding a least-square solution with a previously cal-
Figure 3 | An investigation of the stabilization of several solvated mutant/WT-inhibitor systems. Diagrams (a) and (b) show the plots for trajectory
(frames) vs. backbone RMSD (A˚) in the MD simulation period (2 ns), with regard to the solvated WT-gefitinib and WT-erlotinib systems respectively.
Similarly, diagrams (c) , (d), (e) , (f) and (g) , (h) present the plots for the systems involving L858R, delE746_A750 and delL747_P753insS
respectively.
www.nature.com/scientificreports
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culated hidden layer output matrix. With the generally used sigmoi-
dal function applied as the activation function g(x), the required
number of hidden nodes ~N is regarded as the single controllable
parameter. Our validation system is the leave-one-out cross-valid-
ation, in which we build the classifier 168 times and a different
sample is used for testing in turn each time with the remaining 167
samples used for training. The required number of hidden nodes ~N
in ELMs is adapted from 50 to 500 at a step of 50. For each specific ~N ,
the ELM will be repeated 20 times and the best performance is
retained. The final classification accuracy is calculated by averaging
the classification rates of all 168 classifiers. In order to conduct a
comparison between the case where only themutation feature is used
and the case involving both the mutation feature and personal fea-
tures, we apply the classification model on both these two cases, and
the results are presented in Table 2. As shown in this table, with ~N
ranging from 50 to 500, we obtain average classification accuracies of
81.55% and 68.33% for training and testing respectively in the first
case (using themutation feature alone); while 95.41% and 89.94% are
achieved in the second case (using both mutation and personal fea-
tures). This implies the necessity of incorporating personal features
into the model, and a detailed comparison between the training/
testing accuracies reported in the two cases is shown in Figure 5
(parts e and f). Furthermore, the best testing accuracy 95.83% (for
the second case) is achieved with ~N 5 150, which reflects a very good
prediction result.
Discussion
The field of bioinformatics is developing very rapidly and it makes
the prediction of molecular structure, studies of mutation-induced
drug resistance, and innovative drug discovery more feasible4,11,12. In
this work, we develop a computational model to transfer the geno-
typic data to phenotypic data for specialized subjects, by character-
izing the EGFR-inhibitor interaction patterns and taking personal
features into consideration. The constructed mutant-inhibitor com-
plexes are each solvated into a solvent environment, and a successive
systematic equilibrium is achieved via simulations. We subsequently
characterize the features of a subject using the energy components of
binding free energy (mutation feature) and the specialized personal
information (personal features). The combination of ELMs and
leave-one-out cross-validation produces a successful identification
of resistant subjects with high accuracy.
Personalized medicine/therapy proposes customization of health-
care to individual patients, and the use of genotypic information
plays an important role. Our method can be regarded as a persona-
lized prediction model for drug resistance, based on both the muta-
tion feature and the personal features of a patient. With a high
Figure 4 | Statistics onmutation types and their binding free energies with the two inhibitors.Part (a) shows the statistics of the 37mutation types of our
observed 168 patients. Parts (b) and (d) present the distributions of total binding free energies of the mutants (with WT protein included) with two
inhibitors gefitinib and erlotinib. The red lines and solid blue circles show the binding free energy for the WT EGFR and the L858R mutant respectively.
Parts (c) and (e) display the distributions of the binding free energy components, which encompass VDW, EEL, EPB and ENPOLAR, for the two
inhibitors.
www.nature.com/scientificreports
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prediction rate for drug resistance, our model encourages the
development of personalized medicine/therapy design.
As one of our future works, more accurate and powerful
approaches will be explored to predict the 3D structure of a specific
mutation, based on its sequential information. Homology modeling
will serve as a guiding role34,35. On the other hand, more efficient
strategies will be discovered to reduce the high computational com-
plexity of calculating the binding free energy for a mutant-inhibitor
system. Modern graphics processing units (GPUs) and field pro-
grammable gate arrays (FPGAs) have evolved into high performance
Figure 5 | Statistics on features and classification results of the clinical subjects. Part (a) shows the distribution of mutation feature (total binding
free energy) vs. survival time for the 168 clinical subjects, with each point representing one subject. Similarly, the plot ofmutation feature vs. response level
is displayed in part (b). The distributions of the adopted features (personal 1 mutation) for the 168 subjects are shown in parts (c) and (d), with part
(c) showing the original distribution while part (d) the normalized values. Part (e) provides a comparison between the training accuracies reported in the
case involving themutation feature only (blue, denoted as ‘M’) and the case involving bothmutation feature and personal features (brown, denoted as ‘M
1 P’). Part (f) shows a comparison between the testing accuracies (blue for the first case, and brown for the second).
Table 1 | Description of personal information for the observed patients
No. Abbreviation Description Continuous/Discrete Range
1 age Age of the patient Discrete [0, 4]
2 gender Gender of the patient Discrete [0, 1]
3 smoke Smoking history Discrete [0, 2]
4 PS Performance status Discrete [0, 3]
5 histolog Subtypes of the NSCLC Discrete [1, 7]
6 t_stage Stages describing the development of the
NSCLC
Discrete [1, 4]
7 n_stage Discrete [0, 3]
8 m_stage Discrete [0, 4]
9 o_stage Continuous [3.2, 4.0]
10 bra_mets Brain metastasis Discrete [0, 9]
11 susp_ire Suspension of TKIs Discrete [0, 1]
This table displays the personal information, which incorporates both basic descriptive features (such as age and gender) and some emerged symptoms, for the observed patients.
www.nature.com/scientificreports
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accelerators for parallel computing36–39. With these devices, the com-
putational power can be improved tens or even hundreds of times. In
our future computations, GPUs and FPGAs will be adopted to accel-
erate the computation of binding free energies. Moreover, the bind-
ing free energy library (Supplementary Table 1) can be periodically
updated so that only newly identified mutation types need to be
added to the library. Since the mutation types in a dataset are highly
redundant, the utilization of this library will significantly reduce the
computational load. Thus, more clinical data can be collected and
analyzed in our following studies, which will improve the aforemen-
tioned prediction model and help us update the library based on the
new data. Future studies will bring more benefits to the investigation
of mutation-induced drug resistance and innovative drug design.
Methods
EGFR kinase mutant-inhibitor complex modeling and molecular dynamics (MD)
simulations. First, we predict the structures of EGFR kinase domain mutations
computationally. The scap program handles side chain substitutions and the loopy
program handles residue deletions and insertions. After obtaining the predicted
structures, we optimize them through the QM/MMmechanism in AMBER. Missing
atoms and an octahedron water box (10 angstrom) are added using the tleap program
before we carry out minimization with the sander program. Each structure is initially
partitioned into aQM region for themutated residues and anMMregion for the other
residues, and the system is characterized by an effective Hamiltonian as described in
Equation (1).
Eeff~ y HQMzHQM=MM yj
 zEMM ð1Þ
Here the MM region is handled classically using the AMBER additive force field
(Equation (2)); the QM region and QM/MM interface are formulated with
Hamiltonians.
V(r)~EbondedzEnonbonded
~
X
bonds
Kb(b{b0)
2z
X
angles
Kh(h{h0)
2
z
X
dihedrals
(Vn=2)(1z cos½nw{d)
z
X
nonbij
(Aij=r
12
ij ){(Bij=r
6
ij)z(qiqj=rij)
ð2Þ
Once a refinedmutant structure is obtained, we align it to the template complex 2ITY
or 1M17 containing the WT kinase protein and the drug molecule, to acquire an
original coarse mutant-inhibitor complex. Likewise, we use AMBER to minimize
these complexes and simulate their dynamics in a solvent environment. AMBER
adopts Equation (2) as the basic force field form during molecular dynamics (MD)
simulations, and the ff99SB force field is selected in our work owing to its broad
applications. A simple water box with a 10.0 angstrom buffer around the complex in
each direction is generated, based on the common TIP3P water model. The tleap
program creates the topology and coordinates files of the solvated complex, and
passes them to sander for the later MD run.
An important factor for achieving a stable MD simulation is the equilibrium of a
system. Using AMBER and AMBER TOOLS, we build up a moderate setting for the
equilibration, which encompass minimization, heating, density equilibration and
constant pressure equilibration, leading to an approximately 4-hour run on 12
3.47 GHz processors of our computer. The subsequent MD simulation is performed
on each equilibrated system with a relatively short time of 2 ns, which aims to
compensate for the large computational costs and ultimately leads to a 14-hour run.
In the MD run for a mutant-inhibitor complex, the motion trajectory is collected
every 10 ps to reach a total of 200 frames, which will be used in the following
calculation of the binding free energy.
Molecular binding affinities calculated using MM/PBSA model. The binding free
energy of a receptor-ligand complex in a solvent environment is an important
standard for measuring the binding affinity. Based on the theory of thermodynamic
cycle, the original calculation can be constructed as follows,
DGBind,Solv~DGBind,Vacuum
z(DGSolv,Complex{DGSolv,Ligand{DGSolv,Receptor)
~DGBind,VacuumzDDGSolv
ð3Þ
Here each DG stands for the free energy difference between two distinct states.
DGBind,Solv and DGBind,Vacuum correspond to the free energy difference between the
bound and unbound states of a complex in solvent and vacuum respectively. DGSolv
(DGSolv,Ligand, DGSolv,Receptor and DGSolv,Complex) represents the change of free energy
between the solvated and vacuum states of a ligand, receptor or complex.
Both the free energy difference in vacuum DGBind,Vacuum and the solvation free
energies DGSolv contribute to the calculation of binding free energy DGBind,Solv.
MMPBSA.py in AMBER24 performs Molecular Mechanics/Poisson Boltzmann
Surface Area (MM/PBSA) to derive these free energy differences. DGBind,Vacuum
(Equation (4)) can be captured by averaging the interaction energies DE between the
receptor and ligand. However, the entropy contribution DSNMA is generally neglected
for states with similar entropies, due to high computational expense. Practically,
energy components for this portion incorporate the Van der Waals forces and the
electrostatic interactions between atoms in the MM region. On the other hand, the
solvent free energy DGSolv typically encompasses the polar contribution and the
nonpolar contribution (Equation (5)).
DGBind,Vacuum~DE{TDSNMA ð4Þ
DGSolv~DGpolarzDGnonpolar ð5Þ
Here, the nonpolar contributionDGnonpolar is simply computed by a linearmodel, and
the polar portion DGpolar is approximated by solving the PB equation.
In this work, a parallel version of MMPBSA.py.MPI is implemented on 12
3.47 GHz processors to accelerate the computations. Each previously obtained MD
trajectory, representing a number of conformations, is a major input to MMPBSA. A
single MMPBSA run requires 0.5 hours approximately.
Classification models using extreme learning machines. With the personal
information (age, gender, smoking history etc.) taken into account, we combine them
with the previously acquired energy components of the binding free energy (mutation
feature) as principal features, and predict the response levels of our observed patients
using machine learning techniques.
The fundamental predictionmethodwe adopt is the ELMs. They play an important
role in training single-hidden layer feed-forward neural networks (SLFNs) in
Equation (6) below, and provide a good balance between the computational speed
Table 2 | Classification results with different settings
Number of
Hidden
Nodes ~N
Mutation feature Mutation feature 1 Personal features
Training Time
for each fold
(seconds)
Testing Time
for each fold
(seconds)
Training
Accuracy
(average)
Testing
Accuracy
(average)
Training Time
for each fold
(seconds)
Testing Time
for each fold
(seconds)
Training
Accuracy
(average)
Testing
Accuracy
(average)
50 0.0144 0.0002 0.8155 0.7917 0.0145 0.0004 0.8004 0.8333
100 0.0379 0.0004 0.8155 0.7262 0.0516 0.0002 0.9303 0.8810
150 0.0555 0.0003 0.8155 0.7024 0.1147 0.0003 0.9762 0.9583
200 0.0767 0.0010 0.8155 0.6845 0.1461 0.0006 0.9762 0.9286
250 0.0898 0.0006 0.8155 0.6607 0.1649 0.0005 0.9762 0.9226
300 0.1010 0.0005 0.8156 0.6607 0.1642 0.0005 0.9763 0.9107
350 0.1076 0.0009 0.8155 0.6607 0.1729 0.0007 0.9762 0.9048
400 0.1142 0.0010 0.8154 0.6488 0.1827 0.0007 0.9763 0.8869
450 0.1229 0.0006 0.8156 0.6488 0.1887 0.0009 0.9762 0.8869
500 0.1323 0.0010 0.8155 0.6488 0.1978 0.0009 0.9763 0.8810
This table shows the prediction results of the response level to the specific inhibitors for the observed patients. Two feature sets, one including the mutation feature only while the other involving both the
mutation feature and personal features, are applied for a comparison. Extreme learning machines and leave-one-out cross validation are used in the calculation. The number of hidden nodes varies from 50
to 500 at a step of 50, and the execution time and accuracy are shown in the table.
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and generalization performance25,26.
X~N
j~1
bjg wj
:xizbj
 
~oi,i~1, . . . ,N ð6Þ
Here xi,yið Þjxi[Rn,yi[Rm,i~1, . . . ,Nf g is the training set, ~N and g(x) are the number
of hidden nodes and activation function respectively of the SLFN, and wj and bj
represent the input weights and input biases. The goal is to approximate the training
examples with minimum error between oi (Equation (6)) and yi, which could be
summarized in a matrix form as Equation (7).
Hb~Y ð7Þ
whereH is the hidden layer output matrix. The essential idea of ELMs is to randomly
assign the inputweightswj and biases bj, which leads the training of the above SLFN to
finding a least-square solution b^ of the linear system denoted by Equation (8).
Hb^{Y

~min
b
Hb{Yk k ð8Þ
The algorithm can be summarized as follows:
Algorithm 1: Extreme Learning Machine.
Input:
Training set xi,yið Þjxi[Rn,yi[Rm,i~1, . . . ,Nf g which contains N training exam-
ples;
Activation function g(x);
Number of hidden node ~N ;
Output:
Input weight wj, input bias bj, and output weight b;
. Randomly assign input weight wj and bias bj where j 5 1,…, ~N;
. Calculate the hidden layer output matrix H;
. Calculate the output weight b by b 5 H{Y, where H{ is the Moore-Penrose
generalized inverse of matrix H, and Y~ y1, . . . ,yN½ T .
The generally used sigmoidal function is applied as the activation function g(x),
and the required number of hidden nodes ~N is regarded as a controllable parameter.
In addition, when training the model, we employ the leave-one-out cross-validation
mechanism, which guarantees each sample is used once as the validation data. The
process involves a total number of 168 combinations of partition, training and
validation, and each combination is referred to as a fold. With a specific parameter
setting in each fold, the experiments are repeated 20 times owing to the randomness of
ELMs, and the best performance will be retained. For the overall cross-validation
scheme encompassing 168 folds, we average their results to produce the final one.
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